Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arcellx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACLX
Nasdaq
8731
https://www.arcellx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arcellx Inc
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
- Jan 30th, 2023 2:00 pm
Gilead's (GILD) Application for Trodelvy Gets EMA Validation
- Jan 4th, 2023 4:45 pm
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
- Dec 14th, 2022 3:24 pm
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
- Dec 12th, 2022 3:55 pm
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
- Dec 9th, 2022 9:08 pm
Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead
- Dec 9th, 2022 2:54 pm
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
- Dec 9th, 2022 2:42 pm
Gilead to co-develop Arcellx's multiple myeloma drug
- Dec 9th, 2022 1:46 pm
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress
- Dec 9th, 2022 1:17 pm
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
- Dec 9th, 2022 1:17 pm
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
- Dec 9th, 2022 1:15 pm
We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely
- Nov 30th, 2022 4:08 pm
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
- Nov 14th, 2022 9:00 pm
‘The bear market rally has more room to run,’ Guggenheim says. Here are 2 stocks to bet on
- Nov 14th, 2022 6:13 pm
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
- Oct 27th, 2022 6:37 pm
Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet
- Sep 8th, 2022 1:55 pm
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results
- Aug 15th, 2022 8:00 pm
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel
- Jun 21st, 2022 8:05 pm
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares
- Jun 21st, 2022 8:01 pm
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering
- Jun 16th, 2022 2:47 am
Scroll